Stock Events

TransCode Therapeutics 

$0.3
48
-$0-1.06% Today

Statistics

Day High
-
Day Low
-
52W High
128
52W Low
0.29
Volume
815,820
Avg. Volume
890,020
Mkt Cap
2.17M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

30MarExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-0.4
-0.1
0.21
0.51
Expected EPS
-0.38
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNAZ. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap46.43B
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the genetic medicines space similar to TransCode's RNA-based treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals, Inc. specializes in RNA interference (RNAi) therapies, targeting the same RNA-based technology approach as TransCode.
Ionis Pharmaceuticals
IONS
Mkt Cap6.98B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, making it a direct competitor in the RNA-based drug development field.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap3.51B
Arrowhead Pharmaceuticals, Inc. works on medicines that silence gene expression via RNA interference, competing in the RNA therapy space.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics, Inc. focuses on RNA-targeted drug discovery and development, particularly for rare diseases, similar to TransCode's focus on RNA.
BioNTech
BNTX
Mkt Cap20.32B
BioNTech SE partners with companies to develop mRNA-based drugs for various diseases, competing in the mRNA therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics AG specializes in gene editing, a different but related field to RNA-based therapies, targeting genetic diseases at the DNA level.
Intellia Therapeutics
NTLA
Mkt Cap2.42B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, competing in the broader genetic medicine space that includes RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap411.19M
Editas Medicine, Inc. focuses on gene editing using CRISPR technology, representing competition in the genetic medicine arena, including RNA-based approaches.

Analyst Ratings

3$Average Price Target
The highest estimate is $3.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Show more...
CEO
Employees
10
Country
US
ISIN
US89357L1052

Listings

XNAS
US
RNAZ